Compare ARE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | TGTX |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.9B |
| IPO Year | 1997 | 2008 |
| Metric | ARE | TGTX |
|---|---|---|
| Price | $52.96 | $54.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $56.22 | $49.80 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 11.40% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 1.68 | 0.17 |
| Revenue | ★ $3,026,556,000.00 | $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | $0.15 | $26.69 |
| P/E Ratio | ★ $31.53 | $323.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.41 | $26.76 |
| 52 Week High | $88.24 | $59.30 |
| Indicator | ARE | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 57.45 |
| Support Level | $48.24 | $51.22 |
| Resistance Level | $55.36 | $58.08 |
| Average True Range (ATR) | 1.68 | 2.25 |
| MACD | 0.49 | 0.68 |
| Stochastic Oscillator | 74.47 | 67.83 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.